Toggle navigation
Home
Search
Services
Blog
Contact
About
Phase II Clinical Trial of Dfmo and Nsaidin Colon - Workstatement 45-261975019
University of California Irvine
Search grants from University of California Irvine
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Publications
Comments
Recent in Grantomics:
Your institution
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Sensitivity of the Circadian Clock to Light in Early Childhood
FVIIa for Acute hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial
Artificial Ecology Sink as prophylaxis against viral infection
Deacetylation of mitochondrial proteins protect neurons from ischemic injury
Endocrine Abnormalities in Hereditary Disorders of Connective Tissue
Recently added grants:
At home monitoring for 177Lu DOTATATE treatment personalization
Development of a Novel Lung Function Imaging Modality for comprehensive management of lung cancer
Functional Approaches to Understanding Cancer Aneuploidy: Interrogating the Effects of Chromosome 3p Deletion
Unique targeting of PPAR?/? regulation for cancer prevention and therapy
Mechanisms of Genome Instability in Tumors with DNA Polymerase Epsilon Mutations
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research and Development Contracts (N01)
Project #
N01CA075019-004
Application #
6688678
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
2002
Total Cost
Indirect Cost
Institution
Name
University of California Irvine
Department
Type
DUNS #
City
State
Country
Zip Code
Related projects
NIH 2003
N01 CA
Phase II Clinical Trial of Dfmo and Nsaidin Colon - Workstatement 45-261975019
/ University of California Irvine
NIH 2002
N01 CA
Phase II Clinical Trial of Dfmo and Nsaidin Colon - Workstatement 45-261975019
/ University of California Irvine
Publications
Beeram, M; Tan, Q-T N; Tekmal, R R et al.
(2007)
Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling.
Ann Oncol 18:1323-8
Comments
Be the first to comment on this grant